Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Payables (2016 - 2025)

Mimedx's Payables history spans 15 years, with the latest figure at $14.5 million for Q4 2025.

  • For Q4 2025, Payables rose 96.09% year-over-year to $14.5 million; the TTM value through Dec 2025 reached $14.5 million, up 96.09%, while the annual FY2025 figure was $14.5 million, 96.09% up from the prior year.
  • Payables for Q4 2025 was $14.5 million at Mimedx, up from $11.4 million in the prior quarter.
  • Across five years, Payables topped out at $14.5 million in Q4 2025 and bottomed at $6.9 million in Q3 2021.
  • The 5-year median for Payables is $8.3 million (2022), against an average of $8.7 million.
  • The largest annual shift saw Payables fell 29.02% in 2021 before it soared 96.09% in 2025.
  • A 5-year view of Payables shows it stood at $7.4 million in 2021, then increased by 14.48% to $8.5 million in 2022, then grew by 7.03% to $9.0 million in 2023, then dropped by 18.11% to $7.4 million in 2024, then skyrocketed by 96.09% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Payables are $14.5 million (Q4 2025), $11.4 million (Q3 2025), and $8.5 million (Q2 2025).